本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市新产业生物医学工程股份有限公司（以下简称"公司"）于近日收到 日本特许厅颁发的1项《发明专利证书》，现将本次取得的发明专利具体情况公 告如下： 证券代码：300832 证券简称：新产业 公告编号：2025-038 深圳市新产业生物医学工程股份有限公司 关于公司获得发明专利证书的公告 专利权人：深圳市新产业生物医学工程股份有限公司 发明人：慕海林、徐方园、仇泽峰、程昱、黄任 专利申请日：2023年11月20日 深圳市新产业生物医学工程股份有限公司 发明名称：输送装置及核酸检测装置 日本专利号：第7663662号 授权公告日：2025年04月08日 上述专利保护技术为公司自主研发，本发明应用于全自动核酸检测分析系统 Molecision R8，涉及一种耗材输送装置，通过设置可横向移动的活动板以及可相 对于活动板沿竖向移动的第一承载台，使得本装置能够兼容不同高度的耗材，并 且能够实现耗材在载料位置和取料位置间的快速转移，大幅提高了耗材的转移效 率，进而提高了全自动核酸检测仪的检测速度。 本次取得的发明专利不会对公 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a strong expectation for future returns exceeding the market benchmark by more than 15% over the next 6-12 months [5][14]. Core Insights - The company achieved a revenue of 4.535 billion yuan in 2024, representing a year-on-year growth of 15.41%, and a net profit of 1.828 billion yuan, up 10.57% year-on-year [1][2]. - In Q1 2025, the company reported a revenue of 1.125 billion yuan, a 10.12% increase year-on-year, and a net profit of 438 million yuan, growing 2.65% year-on-year [1][2]. - The company has seen significant growth in its overseas market, with a revenue of 1.686 billion yuan in 2024, marking a 27.60% increase year-on-year [2][3]. - R&D investment reached 454 million yuan in 2024, up 23.92% year-on-year, supporting continuous innovation and product development [2][3]. Revenue and Profit Growth - The company’s revenue and profit have shown steady growth, with reagent income at 3.268 billion yuan (up 14.32%) and instrument income at 1.259 billion yuan (up 18.67%) in 2024 [2]. - The revenue growth rate is projected to be 14.27% in 2025 and 18.55% in 2026 and 2027 [4]. Market Expansion - The company has expanded its domestic market presence, reaching 1,732 tertiary hospital clients by the end of 2024, achieving a coverage rate of 44.93% [3]. - Internationally, the company has established operational systems in 14 core countries, enhancing its brand influence and driving regional growth [3]. Financial Projections - The EPS forecast for 2025 is adjusted to 2.54 yuan, with further projections of 3.11 yuan for 2026 and 3.73 yuan for 2027 [3][4]. - The current price corresponds to a P/E ratio of 21 for 2025, 17 for 2026, and 14 for 2027 [3][4]. Profitability and Valuation Metrics - The company’s gross margin is projected to be 72.1% in 2024, with a gradual decline to 69.4% by 2027 [12]. - The report indicates a consistent ROE, estimated at 21.32% for 2024 and expected to rise to 22.68% by 2027 [12].

Core Insights - The company reported a revenue of 4.535 billion yuan for 2024, a year-on-year increase of 15.41%, driven by growth in overseas market sales [1] - The net profit attributable to shareholders was 1.828 billion yuan, up 10.57% year-on-year, while the non-recurring net profit was 1.720 billion yuan, an increase of 11.19% [1] - In Q4 2024, the company achieved a revenue of 1.121 billion yuan, a 9.75% increase year-on-year, but the net profit decreased by 4.73% to 445 million yuan [1] Revenue Breakdown - Domestic revenue reached 2.843 billion yuan, a 9.32% increase, primarily due to reagent price adjustments post-collection [2] - Overseas revenue was 1.684 billion yuan, a significant growth of 27.67%, with reagent income increasing by 26.47% [2] - The company established subsidiaries in Indonesia, Malaysia, and Thailand, and opened an office in Hanoi, Vietnam, with a successful launch of a subsidiary in South Korea in early 2025 [2] Product Performance - The flagship model MAGLUMI X8 saw stable growth, with annual sales of 1,048 units, bringing the total installed base to 3,701 units by the end of 2024 [2] - The SATLARS T8 fully automated laboratory automation line was successfully launched in June 2024, achieving 87 installations in its first year [3] Financial Metrics - The overall gross margin for 2024 was 72.07%, a slight decrease of 0.89 percentage points year-on-year [4] - The net profit margin decreased by 1.76 percentage points to 40.32% due to various cost factors [4] - In Q4 2024, the gross margin was 71.26%, with a notable decline influenced by accelerated installations of large equipment [4] Future Projections - Revenue forecasts for 2025-2027 are 5.155 billion, 6.010 billion, and 6.810 billion yuan, with year-on-year growth rates of 14%, 17%, and 13% respectively [5] - Projected net profits for the same period are 2.023 billion, 2.422 billion, and 2.794 billion yuan, reflecting growth rates of 11%, 20%, and 15% [5] - Earnings per share (EPS) are expected to be 2.57, 3.08, and 3.56 for 2025, 2026, and 2027 respectively [5]

Investment Highlights - The report highlights the recovery of revenue growth for Yuyue Medical, with a significant increase in overseas sales, achieving a revenue of 7.57 billion yuan in 2024, down 5.1% year-on-year, and a net profit of 1.81 billion yuan, down 24.6% year-on-year [3][8] - Guotai Group's performance shows resilience in its civil explosives business, with a non-net profit growth of 17.09% year-on-year in Q1 2025, despite a slight revenue decline of 1.26% [12][13] - China Merchants Highway reported a revenue of approximately 2.803 billion yuan in Q1 2025, down 7.24% year-on-year, but net profit improved by 2.74% due to cost control and increased investment income [16][17] - Shenzhen Gas's main business in urban gas sales showed growth, with a revenue of 28.348 billion yuan in 2024, down 8.34% year-on-year, but a net profit increase of 1.19% [21][22] - New Industry's overseas business continued to grow rapidly, with a revenue of 4.535 billion yuan in 2024, up 15.41% year-on-year, and a net profit of 1.828 billion yuan, up 10.57% [25][26] - Huali Group's revenue in Q1 2025 grew by 12% year-on-year, driven by new brand collaborations and strong sales of sports shoes [30][31] - Bohai Leasing, a leading aircraft leasing company, reported a significant increase in aircraft sales revenue, reaching 12.7 billion yuan in 2024, up 61.08% year-on-year, driven by a strong aircraft market [35][36] - Weimao Electronics, an industrial intelligent connection control solution manufacturer, achieved a revenue of 260 million yuan in 2024, up 13.69% year-on-year, with a focus on expanding into emerging fields [39][40] Company-Specific Summaries Yuyue Medical (002223.SZ) - The company experienced a revenue decline in 2024 due to high base effects from the previous year, but Q1 2025 showed a recovery with a 9.2% year-on-year increase in revenue [3][9] - The product mix has led to a slight decrease in gross margin, with a 50.1% gross margin in 2024, down 1.2 percentage points year-on-year [10] - The company maintains a strong financial position with 7.08 billion yuan in cash and no short-term or long-term loans [10] Guotai Group (603977.SH) - The civil explosives business showed growth, with a revenue of 327 million yuan in Q1 2025, up 1.4% year-on-year [13][14] - The company faced a decline in electronic detonator sales but saw an increase in explosive engineering revenue [14][15] - The gross margin for Q1 2025 was 32.72%, down 0.5 percentage points year-on-year, but the non-net profit remained stable [15] China Merchants Highway (001965.SZ) - The company is actively pursuing expansion projects, including the ongoing reconstruction of key highways [17][18] - The net profit forecast for 2025-2027 is expected to grow steadily, with projected profits of 5.74 billion yuan in 2025 [18] Shenzhen Gas (601139.SH) - The urban gas sales volume increased by 2.78% in 2024, with significant growth in the Greater Bay Area [22] - The company is expected to benefit from lower upstream gas prices and increased sales volume [22][24] New Industry (300832.SZ) - The company reported a strong performance in overseas markets, with a 27.67% increase in overseas revenue [27] - The gross margin for 2024 was 72.26%, with a focus on expanding the product lineup in the chemical luminescence sector [28] Huali Group (300979.SZ) - The company maintained a strong partnership with major brands, resulting in a 12.34% revenue increase in Q1 2025 [30][31] - The company is expanding production capacity to meet growing demand, with a workforce increase of 17% [31] Bohai Leasing (000415.SZ) - The company is positioned as a global leader in aircraft leasing, with a fleet size of 1,158 aircraft [36] - The net profit forecast for 2025-2027 is expected to grow significantly, with a projected profit of 1.913 billion yuan in 2025 [37] Weimao Electronics (833346.BJ) - The company is focusing on the automotive and industrial automation sectors, with a projected growth in the vehicle wiring harness market [40][41] - The company is expanding its production capabilities to meet increasing demand in emerging markets [41]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Insights - The company's performance in 2024 met expectations, with a revenue of 4.535 billion yuan (up 15.41% year-on-year) and a net profit of 1.828 billion yuan (up 10.57% year-on-year). The growth is steady and aligns with forecasts [5] - In Q1 2025, the company achieved a revenue of 1.125 billion yuan (up 10.12% year-on-year) and a net profit of 438 million yuan (up 2.65% year-on-year). The domestic performance faced pressure due to inter-provincial alliance procurement policies, while overseas business continued to grow steadily [5] - The company has adjusted its profit forecasts for 2025-2026 and added a new forecast for 2027, expecting net profits of 2.049 billion yuan, 2.488 billion yuan, and 3.004 billion yuan for 2025, 2026, and 2027 respectively [5] - The company's overseas revenue reached 1.684 billion yuan in 2024 (up 27.67% year-on-year), accounting for 37% of total revenue, indicating strong growth in international markets [7] Financial Summary - In 2024, the company reported total revenue of 4.535 billion yuan, with a year-on-year growth of 15.4%. The net profit for the same year was 1.828 billion yuan, reflecting a growth of 10.6% [8] - The projected revenues for 2025, 2026, and 2027 are 5.126 billion yuan, 6.150 billion yuan, and 7.380 billion yuan respectively, with expected year-on-year growth rates of 13.0%, 20.0%, and 20.0% [8] - The company's gross margin is projected to be 71.0% in 2025, with a slight increase to 71.9% by 2027 [11]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is experiencing rapid growth in overseas business and optimizing its global installed structure [5] - Revenue forecasts for 2025-2027 are projected at 51.63 billion, 59.61 billion, and 69.28 billion RMB, with year-on-year growth rates of 13.84%, 15.45%, and 16.22% respectively [6] - Net profit attributable to the parent company for the same period is expected to be 20.12 billion, 23.43 billion, and 27.38 billion RMB, with growth rates of 10.06%, 16.41%, and 16.85% respectively [6] - The current price-to-earnings (P/E) ratios are 21x, 18x, and 15x for the years 2025, 2026, and 2027 [6] Financial Performance Summary - In 2024, the company achieved a revenue of 45.35 billion RMB (yoy +15.41%) and a net profit of 18.28 billion RMB (yoy +10.57%) [8] - For Q1 2025, the company reported a revenue of 11.25 billion RMB (yoy +10.12%) and a net profit of 4.38 billion RMB (yoy +2.65%) [8] - The company’s gross margin for 2024 was 72.26%, a slight decrease of 0.86 percentage points year-on-year, primarily due to an increase in the sales proportion of large and medium-sized instruments [8] - The company plans to continue increasing its investment in chemiluminescence and in vitro diagnostic products, with the launch of higher throughput instruments [8] Market Position and Strategy - The company has established operational systems in 14 core countries overseas, with significant sales growth in the Indian market, which exceeded 200 million RMB in 2024 [8] - The domestic revenue reached 28.43 billion RMB in 2024, with a year-on-year growth of 9.32%, driven by the promotion of high-speed instruments and production lines [8] - The company aims to enhance its market share in large medical institutions, achieving a coverage rate of 44.93% in tertiary hospitals by the end of 2024 [8]

Core Insights - The company achieved a revenue of 4.535 billion yuan in 2024, representing a year-on-year increase of 15.41%, and a net profit attributable to shareholders of 1.828 billion yuan, up 10.57% year-on-year [1] - The company plans to distribute a cash dividend of 13 yuan per 10 shares (tax included) to all shareholders [1] Domestic Market Performance - In 2024, the domestic market generated a revenue of 2.843 billion yuan, reflecting a year-on-year growth of 9.32% [2] - The company continued its large customer marketing strategy, promoting high-throughput chemiluminescence immunoassay analyzers MAGLUMI X8 and MAGLUMI X6, and the automated line product SATLARS T8 [2] - The company installed 1,641 chemiluminescence immunoassay analyzers in domestic markets, with large machine installations accounting for 74.65% [2] - By the end of 2024, the company’s products served 1,732 tertiary hospitals, achieving a coverage rate of 44.93% [2] - Domestic reagent business revenue grew by 9.87% year-on-year despite price pressures from inter-provincial alliance procurement [2] - In Q1 2025, domestic market revenue showed a slight increase of 0.11% year-on-year due to the impact of procurement policies [2] International Market Performance - In 2024, the overseas market achieved a revenue of 1.684 billion yuan, marking a year-on-year increase of 27.67% [3] - The reagent business grew by 26.47% year-on-year, driven by increased instrument installations [3] - The company has established a significant overseas brand advantage through localized operations and has set up subsidiaries in Indonesia, Malaysia, Thailand, and a representative office in Vietnam [3] - By early 2025, the company successfully established a subsidiary in South Korea, and has operational systems in 14 core countries [3] - The sales revenue in the Indian market surpassed 200 million yuan in 2024, indicating a shift from regional expansion to in-depth management [3] - In Q1 2025, overseas business continued to grow steadily, with a year-on-year revenue increase of 27.03% [3] Product Development and Innovation - The flagship model MAGLUMI X8 continues to lead the market, with annual sales/installations of 1,048 units in 2024, bringing the total installations to 3,701 units [4] - The company launched the higher throughput MAGLUMI X10 in February 2024, enhancing user experience for medical terminals [4] - The company offers 224 types of chemiluminescence immunoassay reagents globally, with 198 having EU market access [4] - The SATLARS T8 fully automated laboratory line was successfully launched in June 2024, achieving 87 installations in its first year [4] - The company has made significant breakthroughs in small molecule testing, launching 12 new dual-antibody sandwich method reagents [4] Future Outlook - The company maintains a "recommended" rating, focusing on the in vitro diagnostic field and expanding both domestic and international markets [5] - Despite pressures from procurement policies, the company expects EPS for 2025-2027 to be 2.69, 3.32, and 4.10 yuan respectively [5] - The company anticipates that strong installation numbers and an increasing share of mid-to-large machines will drive reagent volume growth [5]

Performance Overview - In 2024, the company achieved a total revenue of 4.535 billion, representing a year-on-year increase of 15% [1] - The net profit attributable to shareholders was 1.828 billion, up 11% year-on-year, while the net profit excluding non-recurring items was 1.720 billion, also up 11% [1] - In Q4 2024, the company reported revenue of 1.121 billion, a 10% increase year-on-year, but the net profit attributable to shareholders decreased by 5% to 445 million [1] - In Q1 2025, revenue was 1.125 billion, a 10% increase year-on-year, with net profit attributable to shareholders at 438 million, up 3% [1] Operational Analysis - The company experienced stable growth in annual performance, with an increasing proportion of high-end models [2] - Domestic revenue reached 2.843 billion in 2024, a 9.32% increase, with 1,641 units of chemiluminescence immunoassay analyzers installed, and large machines accounting for 74.65% of installations [2] - Overseas revenue was 1.684 billion, a significant increase of 27.67%, with 4,017 units sold and high-end models making up 67.16% of sales [2] - In Q1 2025, domestic revenue faced pressure due to inter-provincial alliance procurement policies, showing only a 0.11% increase, while overseas business maintained a strong growth rate of 27.03% [2] R&D and Innovation - The company invested 454 million in R&D in 2024, accounting for 10% of total revenue [3] - The high-throughput MAGLUMI X10 chemiluminescence immunoassay analyzer was launched in February 2024, enhancing user experience [3] - The fully automated nucleic acid detection analysis system, Molecision R8, received EU market access approval in March 2024, with domestic registration ongoing [3] Profit Forecast and Valuation - The company forecasts net profits attributable to shareholders of 2.148 billion, 2.648 billion, and 3.209 billion for 2025-2027, representing year-on-year growth rates of 18%, 23%, and 21% respectively [4] - The current price corresponds to a PE ratio of 19, 16, and 13 for the years 2025, 2026, and 2027 [4]

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.2400 | 0.3800 | -36.84 | 0.5300 | | 每股净资产（元） | 10.1 | 9.06 | 11.48 | 8.81 | | 每股公积金(元) | 7.21 | 5.04 | 43.06 | 5.04 | | 每股未分配利润(元) | 2.04 | 2.70 | -24.44 | 2.51 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 4.76 | 3.84 | 23.96 | 3.74 | | 净利润(亿元) | 0.26 | 0.41 | -36.59 | 0.57 | | 净资产收益率(%) | 2.52 | 4.12 | -38.83 | 6.08 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 2950.17万股，累计占流通股比： 30.02%， ...

三、分红送配方案情况 10派2元(含税) 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 5365.17万股，累计占流通股比： 53.62%，较上期变化： -27.36万股。 | 名称 | 持有数量(万股) | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 李建波 | 2410.80 | 24.09 | 不变 | | 李小红 | 672.00 | 6.72 | 不变 | | 上海深云龙企业发展有限公司 | 640.08 | 6.40 | 不变 | | 河南中证开元创业投资基金(有限合伙) | 484.63 | 4.84 | 不变 | | 诺安先锋混合A | 349.56 | 3.49 | 不变 | | 陈秋航 | 199.92 | 2.00 | 不变 | | 郭嫩红 | 168.00 | 1.68 | 不变 | | 诺安优选回报混合 | 164.48 | 1.64 | -27.36 | | 民权县创新产业（300832）投资基金(有限合伙) | 137.85 | 1.38 | 不变 | | 安阳普闰高新技术产业投资基金(有限合伙) | 13 ...